WARRENDALE, Pa., June 23, 2026 (GLOBE NEWSWIRE) — ECM Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K253521) for ECMT-100 WMD,…
Read MoreFDA allowing this technology to move forward to clinical investigation marks key milestone for regenerative hydrogel platform in treating complex colorectal conditions. Warrendale, PA – May 5, 2025…
Read MorePITTSBURGH–(BUSINESS WIRE)–ECM Therapeutics, a clinical stage regenerative medicine company pioneering the development of Extracellular Matrix-based therapeutics for the treatment of unmet medical needs, announces a collaboration with the Louis…
Read MoreECM Therapeutics is proud to be the industry partner for this MTEC award to develop a temperature stable and ready-to-use ECM Hydrogel that initiates rapid and sustained hemostasis.
Read MoreMacrophages are capable of extreme plasticity and their activation state has been strongly associated with solid tumor growth progression and regression. Although the macrophage response to extracellular matrix…
Read MoreIntracerebral implantation of neural stem cells (NSCs) to treat stroke remains an inefficient process with
Read MoreAlarmins, sequestered self-molecules containing damage-associated molecular patterns, are released during tissue injury to drive innate immune cell proinflammatory responses. Whether endogenous negative regulators controlling early immune responses are…
Read MoreDr. Stephen Badylak, Dr. Blair Jobe, Dr. Prateek Sharma, and Dr. Bas Weusten invite you to a Cocktail Reception at Roy’s San Diego Waterfront.
Read MoreIn tissue engineering and regenerative medicine, a biomaterial provides mechanical support and biochemical signals to encourage cell attachment and modulate cell behaviour. Nature’s template for a biomaterial is…
Read MoreECM Therapeutics, Inc. ("ECMT") has obtained worldwide exclusive rights from the University of Pittsburgh for an extensive patent portfolio in certain fields of use based upon Extracellular Matrix…
Read More